Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1356225 in Overweight or Obesity
NCT04447261Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing BI 1356225 with Placebo (2 arms). Primary endpoint: The percentage of subjects with drug-related adverse events up to 40 days. Started Jun 2020; status: completed.
02
Drugs
BI 1356225
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04447261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447261.